INTRODUCTION
Lung cancer is the leading cause of death for men and women in the United States and worldwide due to the inability to detect early stage disease and ineffective treatments for advanced disease (1) . In a large randomized trial, low dose spiral computerized tomography (LDCT) was recently shown to identify early stage lung cancer and as a consequence, reduce lung cancer mortality (2). LDCT is likely to become the first approved screening and early detection test for lung cancer but it is plagued by a high false positive rate (2). There is a need to develop complementary screening and early detection tools based on molecular changes due to tumorigenesis. Given that our knowledge of the molecular biology of smoking induced lung cancer has dramatically increased over the past few years this approach is plausible. To date this effort has been focused on the identification of genomic and/or proteomic signatures in a variety of different specimen types with limited success (3) . A broader strategy that incorporates additional cancer characteristics is needed.
Protein glycosylation is one of the major post-translational modifications, and it has been proposed as a new paradigm in biomarker discovery and the search for drug targeting leads (4) . Glycans are enzymatically synthesized by glycosyltransferases and, due to the different glycosidic linkages, have a large structural heterogeneity. Glycosylation of the proteins plays key roles in cell-cell and cell-matrix interactions as well as cellular differentiation and proliferation (5) (6) (7) . It is therefore not surprising that, using numerous lectin-binding studies, glycans have been reported to be differentially expressed in tumor tissue compared to controls (8) , and that differential expression of glycosylation related 6 genes has been described (9) . Furthermore, several of the proteins currently used as biomarkers for cancer in blood are highly glycosylated (10) (e.g. CA125 (11) , PSA (12), CA19-9), indicating the potential importance of protein glycosylation in cancer, and the potential of protein glycosylation analysis in disease identification and treatment.
Advances in technology, particularly the use of mass spectrometry for glycan profiling and identification (13) (14) (15) (16) , now allow for a more structure specific strategy (17) .
Mass spectrometry in itself can only determine a glycan's composition, i.e. the number and type of monosaccharides it consists of, but does not allow identification of the specific glycosidic linkages. The use of a complementary separation technique, such as HPLC is needed to allow structure specific analysis. A recent study addresses the glycosylation of colorectal cancer tissues compared to controls using mass spectrometric techniques (18) .
Among the differentially expressed glycan compositions observed were decreased levels of structures containing a bisecting GlcNAC, while levels of sulfated and paucimannosidic glycans as well as glycans containing sialylated Lewis epitopes were increased (18) .
The glycosylation pattern of the membrane fraction of colorectal cell lines has also been compared to the glycosylation of the membrane fraction of epithelial cells derived from colorectal tumors (19) . It was observed that the membrane glycosylation of the cell lines differed from the glycosylation of the tumor cells, indicating that cell lines may not always provide biologically relevant glycosylation patterns. Therefore, further studies towards the characterization of differential glycosylation patterns of tumor tissue compared to non-malignant tissue are highly desirable. By elucidating disparate glycosylation patterns between malignant and non-malignant lung tissue it allows us to gain greater insight into the underlying biological mechanisms of aberrant glycosylation in 7 lung cancer. We anticipate that these results will then be used as starting point for the further development of clinical glycan applications in the fields of imaging, drug targeting and blood biomarkers.
In this study, we apply a nano HPLC coupled with time-of-flight mass spectrometry (nLC-TOF-MS) based method with a porous graphitized carbon (PGC) stationary phase for the separation of N-glycans released from lung adenocarcinoma tissue samples and nonmalignant control tissue from the same individual. The method has been shown to be highly stable (20) with an average inter-day coefficient of variation of 4 %, determined on log10-transformed integrals and we previously determined the differential glycosylation profiles and a candidate biomarker panel for ovarian cancer using this method (21) . The Nglycans are analyzed twice: once in unreduced form at the compositional level, and once in reduced form at the level of individual glycan structures, which are identified using our inhouse library for structural identification (22) . Differential glycan compositions and structures are identified and gene expression data from a published study (23) is used to further address the underlying changes in the N-glycan biosynthetic pathway and to further understand lung adenocarcinoma tumor glycobiology.
EXPERIMENTAL SECTION

Human samples
Forty-two de-identified malignant and adjacent normal lung tissue specimens were obtained from the New York University biorepository. All samples originated from patients who were current or former smokers with a diagnosis of lung adenocarcinoma (Stages I-IIIA). Informed consent was obtained from all 42 patients. The study was conducted in 8 accordance with institutional ethics committee approval at New York University and the University of California, Davis. Residual tumor and adjacent non-malignant tissue was harvested from the resected lung after routine pathological protocols were completed. Two to three tissue pieces were aliquoted into 1.5 ml Nunc vial, and then immediately placed in liquid nitrogen. After transport in liquid nitrogen, each vial was barcoded, and stored at -80 o C until analyzed. All specimens were clinically annotated for age, gender, race, histology, smoking status, pack-years and stage of disease. Fortyone patients had stage I and 1 patient had stage IIIA disease. The average age of the cohort was 70.2 (±11.3) years and consisted of 13 males and 29 females. Six patients were current smokers and 36 patients were former smokers; their average pack-year was 33.2 (±24.7).
Homogenization of lung cancer tissue specimens
All procedures were performed on dry ice to keep the samples cold. Depending on the weight of the tissue specimens, they were cut into either three (if >10.0 mg) or two pieces (if <10.0mg) and all pieces from the same specimen were placed in a single 1.5 ml eppendorf tube. Then samples were washed using 1 ml cold PBS (Sigma-aldrich, St.Louis, MO) by pipette mixing and subsequent aspiration to remove remaining blood. 100 μl of HB buffer (0.25 M sucrose, 20 mM Hepes-KOH and 10 μl 1:10 protease inhibitor cocktail (Roche, Basel, Switzerland) per 10 ml buffer, pH 7.4) was added to each of the samples, which were then homogenized using a Bullet Blender Storm for 3 min at speed 8 using prepacked tubes for hard tissues (Wisbiomed, San Mateo, CA) (24).
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N-glycan sample preparation
To assess the stability of the N-glycan sample preparation procedure, one standard serum sample (Sigma-aldrich, St.Louis, MO) was included after every ten tissue samples and as the first and last sample. The sample preparation procedure for serum is slightly different compared to tissue (see below), but all steps were performed in parallel for both the tissue and standard serum samples to ensure accurate sample preparation of the tissue samples.
Fifty μl of 300 mM NH4HCO3 (Sigma-aldrich, St.Louis, MO) with 15 mM Dithiothreitol (DTT, Sigma-aldrich, St.Louis, MO) was added to each of the tissue homogenates, while 25 μl of 200 mM NH4HCO3 with 10 mM DTT was added to 11 aliquots of 25 μl of a standard serum sample. Proteins were denatured by heat using four cycles of alternating between boiling water (100 °C) and room temperature (25 °C) water for 15 s each and subsequently glycans were enzymatically released by addition of 2 and 1 μl of PNGaseF (New England Biolabs, Ipswich, MA) to the tissue-and the serum samples, respectively and 16 h. incubation at 37°C. Deglycosylated proteins were precipitated using 600 and 200 µL of icecold ethanol for the tissue-and serum samples, respectively. After centrifugation, the supernatant containing the glycans was transferred to a 96-wells plate according to the plate layout in supplementary Figure SF1 and brought to dryness in vacuo.
N-linked glycans released by PNGaseF were purified using graphitized carbon SPE plates with 40 µL bed volume (Glygen, Columbia, MD), essentially as described earlier (20) . Wells of the SPE plate were conditioned using 2 x 200 µL of 80% ACN containing 0.1% TFA (EMD chemicals, Gibbstown, NJ), followed by 3 x 200 µL of water. Glycan 10 samples were reconstituted in 400 μL of water and subsequently loaded onto the wells.
Cartridges were washed using 7 x 200 µL of water and N-glycans were eluted using 2 x 200 µL of 40% ACN containing 0.05% TFA. Samples were dried in vacuo and reconstituted in water prior to analysis. 50 µL water was used for the standard serum samples and tissue samples <10.0 mg, while 100 µL water was used for tissue samples >10.0 mg.
Glycan reduction
Glycan reduction was essentially performed as described earlier (22) . Briefly, 44 μl of a 2M NaBH4 (Sigma-aldrich, St.Louis, MO) solution in water were added to 44 μl of reconstituted unreduced glycan sample in a 96 wells plate. The plate was incubated at 65°C for 1 h and the reduced glycans were then immediately purified using PGC SPE as described earlier. Samples were dried in vacuo and reconstituted in 50 µL water prior to analysis.
nHPLC-chip-TOF-MS analysis
N-glycans were analyzed as described before (20) (20, 25) . Data was loaded into Masshunter ® qualitative analysis, and glycan features were identified and integrated using the Molecular Feature Extractor algorithm. First, signals above a signal to noise threshold of 5.0 were considered.
Then, signals were deconvoluted using a tolerance of m/z 0.0025 ± 10 ppm. The resulting deconvoluted masses were subsequently annotated using a retrosynthetic theoretical glycan library which was previously developed (26) and contained 331 possible N-glycan compositions. A 15 ppm mass error was allowed. Glycan compositions, retention times and peak area were exported to csv-format for further evaluation.
Statistical Analysis
Prior to statistical analysis, raw peak areas were total quantity normalized based on the underlying assumption that the total amount of ionized glycans that reach the detector is similar for different samples and glycan profiles for each data set. Glycans detected in 12 fewer than 70% of samples were discarded from downstream analysis to reduce the bias that could be induced by imputation for missing not at random. Unobserved values for any remaining undetected glycans below the predefined detection limit were imputed as onehalf of the glycan-specific minimum of the observed values. Finally, the normalized data were log2 transformed to reduce the influence of extreme values and to meet homogeneity of variance assumptions. Statistical analyses were conducted in R 3.0.1 language and environment.
We conducted a partial least squares regression with linear discriminant analysis (PLS-LDA) to assess whether glycomic profiles could separate malignant from nonmalignant tissue samples. To adjust for covariates, we regressed intensity values on age, gender and smoking history and used the residuals, further scaled to a variance of one, in the PLS-LDA. Leave-one-out cross validation was used to estimate the classification accuracy, sensitivity and specificity of the PLS-LDA using one through 10 latent components.
We conducted a differential analysis to identify specific glycans significantly differentially-regulated between cancer tissue and control samples. Two approaches to the differential analysis were used. First, we used paired sample t-tests for univariate analysis without adjustments for covariates. Second, for multivariate analysis we used a mixed effect model in order to take into account age, gender and smoking history as covariates.
For the mixed effect analysis, a random effect was included for each patient to account for correlation of glycan intensities in tissue samples from the same patient. Cancer status of the tissue sample (malignant vs. non-malignant), age, gender and smoking history (packyears) were included as fixed effects. A chi-square test was used to determine significance 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 13 of differences in intensity values between malignant and non-malignant tissue samples.
For both analyses, false discovery rates (FDR) were calculated to account for multiple testing.
Gene expression
Landi et al. previously performed gene expression analysis using HG-U133A Affymetrix chips on fresh frozen tissue samples of adenocarcinoma and paired noninvolved lung tissue from current, former and never smokers (23) . Preprocessed expression data for 27 glycosyltransferases and glycosidases, were extracted from the GENT database (27) . Only matched pairs of current and former smokers were analyzed to mimic the inclusion criteria of the glycomics study. This resulted in a dataset originating from paired malignant and non-malignant samples from 22 patients that were current (12) or former (10) smokers. The gene expression data was analyzed using the same statistical methods for differential analysis as described above. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14 from three samples showed very low intensities (seen supplementary Figure SF3 ) compared to the other samples during the assessment of data quality and were excluded from all further statistical analyses. Because these samples were low in both the reduced and reduced analyses, it is not likely that these low intensities were due to instrument failure, but rather sample preparation difficulties. An overview of the patient characteristics of the 39 remaining individuals is provided in Table 1 . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 15 0.05) in cancerous tissue compared to controls ( Table 2) . One additional glycan composition (Hex5HexNAc4NeuAc2) was shown to be significant when adjusted for the covariates. Interestingly, the levels of several oligomannose type glycans were upregulated. This is concordant with previous studies in human colorectal tissue (18) and mouse breast cancer tissue (28). Furthermore, levels of fully galactosylated glycans, some which were of the hybrid type and mostly without fucose, were decreased in cancerous tissue while levels of non-or lowly galactosylated glycans mostly with fucose were increased. These differences, which are further illustrated in Figure 2 , have thus far not been reported in lung cancer or other cancer tissue studies.
Differential glycan compositions in cancer tissue compared to controls
Differential glycan composition with chemical reduction of glycans
The preceding results showed that glycan compositions were clearly differential in lung cancer tissue compared to controls; however, these compositions are often comprised of several glycan structures (isomers). To further elaborate the glycan structures that are differentially expressed in lung adenocarcinoma tissue, the glycans were reduced to avoid separation of the reducing end anomers and subsequently re-analyzed using nLC-PGCchip-TOF-MS. Unexpectedly, more glycan compositions were consistently observed in the reduced samples compared to the unreduced set (73 vs 45 compositions, respectively).
The reason for the increase in composition is not yet clear. Unreduced glycans separate according to the anomeric character of the reducing end. Each compound is then separated into two forms. Reduction leaves the compound with a single structure thereby decreasing the total number of peaks. The differences could be issues associated with the peak capacity. Further exploration is needed, but this does not affect the results. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   16 The dataset comprising of reduced glycans was assessed at the level of glycan compositions to evaluate whether similar differential results were obtained as compared to the dataset comprising unreduced glycans. The reduced glycan compositions were used to conduct a PLS-LDA analysis to assess whether the global glycomic profile could separate adenocarcinoma tissue from control. The results are summarized in Figure 1b . As with the unreduced analysis, separation between the cancer tissues and the control tissues is observed, indicating the differentiating potential of the reduced glycan compositions in adenocarcinoma.
The differential analysis results with and without adjustment for the covariates are shown in Table 2 . Again, glycan compositions were observed to be significantly (FDR < 0.05) altered in cancerous tissue compared to controls in higher numbers compared to the unreduced samples (22 compositions vs 15 compositions, respectively). However, the results are essentially the same: The levels of several oligomannose type glycans were upregulated. Decreased levels of some hybrid type glycans as well as fully galactosylated glycans mostly without fucose were observed and levels of the N-glycan core (Hex3HexNAc2) with and without fucose as well as two fucosylated, lowly galactosylated tetraantennary glycans were increased. These results show the similarities of the unreduced and reduced sets and indicate that the analysis of reduced glycans is feasible, thus allowing for glycan structure specific determination of differential glycosylation in adenocarcinoma. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 With the glycans reduced, each glycan structure is represented by one signal. This allows for the annotation of actual structures to each of the signals. Structural identification was performed by comparing retention times and accurate masses to an Nglycan database. Here, we used our in-house build library, which is based on serum Nglycans (22) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 18 type were downregulated. For several glycan compositions multiple structures were shown to be significant. While the structures of the same composition were typically all altered in the same direction, the two glycans with composition Hex4HexNAc3Fuc1NeuAc1 were differentially expressed in opposite directions. Because of the opposite expression, composition Hex4HexNAc3Fuc1NeuAc1 was not significant in the compositional analysis, and the differential expression of these glycan structures would thus be missed in a compositional analysis. These results therefore show the potential of the glycan structure specific differentiation. The specific structures of the two differentially expressed glycans of composition Hex4HexNAc3Fuc1NeuAc1 are not yet known. Therefore, further structure elucidation studies will be necessary to evaluate the full biological effects of the different glycan isomers.
Differential glycan structures in cancer compared to controls
Expression of glycosylation-related genes in adenocarcinoma
Glycans are the product of glycosyltransferases and therefore it is to be expected that differential glycan patterns are reflected in differential glycosyltransferase expression. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 19 MGAT2, MGAT3, MGAT4B, B4GALT2, FUT1, FUT2, FUT3, FUT6 and FUT8) were found differentially expressed (FDR<0.05) in the differential analyses, with and without adjustment for age and gender as covariates ( Table 4) .
DISCUSSION
This report describes a detailed analysis of the differential N-glycosylation profile of early stage lung adenocarcinoma tissue compared to paired non-malignant lung control tissue. Samples were chosen to evaluate the early indications of glycosylation changes due to tumorigenesis. Glycosylation profiles were first obtained from the native, unreduced glycans, but to allow for structural identification, a second analysis was performed upon reduction. This yielded 29 differentially expressed glycan structures. To further assess the regulation of the altered glycosylation, the glycomics data was compared to gene expression data from lung adenocarcinoma tissue compared to non-malignant lung tissue, which was publicly available (23) . While it would have been more ideal to have gene expression data on the same tissue samples, we did not have more tissue material available.
By analyzing unreduced glycans we have previously been able to identify differential glycosylation patterns in the serum of ovarian cancer patients (21, 30) , lung cancer patients (29) and prostate cancer patients (25) . However, structural identification is difficult when N-glycans are not reduced due to the separation of the reducing end anomers. In this study, we showed that the analysis of reduced N-glycans yields very similar, though extended results, as more compositions can be observed. This resulted in more significantly different compositions (Table 2) . Furthermore, the separation of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   20 reduced N-glycans using a PGC stationary phase in combination with our in-house Nglycan library allowed us to identify for the first time 29 glycan structures that were differentially expressed in lung cancer tissue. Notably, two glycans of composition Hex4HexNAc3Fuc1NeuAc1 were shown to be differentially expressed in the opposite direction ( Table 3 ). The level of the overall composition was therefore not significantly altered ( Table 2 ). This indicates the value of structure specific analysis for the identification of differentiating glycans. However, when the predictive value of the three datasets (unreduced N-glycan compositions, reduced N-glycan compositions and reduced N-glycan structures) were compared, they each yielded very similar results, indicating that for differential profiling (i.e. biomarker) studies a composition specific analysis is likely sufficient.
The glycomics analysis indicated that high mannose type glycans are consistently increased in lung adenocarcinoma tissue (Tables 2 and 3 ). Potentially this could be caused by decreased levels of MGAT1, which indicate lower transformation of high mannose type glycans to hybrid type glycans (Table 4, Figure 4 ). Increased levels of highmannose type glycans have previously been associated with breast cancer progression (28). Levels of high mannose type glycans were also enhanced upon TGF-β induced epithelial-mesenchymal transition in mouse mammary gland epithelial cells (31), indicating a possible role in cancer progression. However, in serum samples of ovarian cancer patients, high mannose type glycans were shown to be decreased (21, 32) . This is likely a reflection of the largely different protein profile of serum compared to tissue.
The level of fucosylation, especially core fucosylation, was also increased in cancer compared to non-malignant tissue (Table 2, Figure 2) . Comparison to previously 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 established gene expression data indicated a possible regulatory role for FUT 8, as increased expression of FUT8, the fucosyltransferase that is known to catalyze the addition of the α1-6 linked fucose to the core GlcNAc (33) was observed (Figure 4, Table 4 ).
Increased levels of core fucosylation have previously been observed in sera of prostate cancer patients (34) . Furthermore, increased gene expression levels of FUT8 have been observed in several cancers including lung (35) , ovarian (36) , thyroid (37) and colorectal (38) cancers, and that was associated with poor prognosis in colorectal cancer (38) .
Recently, a mechanism for the upregulation of FUT8 during the transition from epithelial to mesenchymal type cells was proposed (35) , and it is anticipated that FUT8 or core fucosylated cancer specific antigens could be excellent drug targets. Indeed, core fucosylated proteins have been proposed as biomarker for hepatocellular carcinoma (HCC) (39) (40) (41) ; however, a recent study did not find increased levels of core fucosylation in HCC tissue (42) .
In this study we found levels of hybrid type glycans to be decreased in lung adenocarcinoma tissue. This finding was supported by the decreased expression of MGAT1 and the increased expression of MGAT2 in adenocarcinoma tissue (Table 4) , which would theoretically result in decreased levels of hybrid type glycans (Figure 4) . We previously reported on decreased levels of four hybrid type glycans in sera of ovarian cancer patients (21) , but to our knowledge, hybrid type glycans have not typically been identified to be differentially expressed in cancer.
Galactosylation is well known to be affected in serum of individuals with several inflammatory diseases; particularly the galactosylation of immunoglobulin G is typically decreased (43) (44) (45) (46) . Here, we report decreased levels of galactosylation in the tissue 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   22 samples of adenocarcinoma patients. The gene expression of one of the enzymes catalyzing the addition of a galactose to a GlcNAc residue was significantly increased (B4GALT2, see Table 4 ), while the expression of the other gene with that functionality was not altered (B4GALT1) and previous studies indicate that both transferases were upregulated in breast cancer tissue (9) . The gene expression analysis was performed on different samples which might explain this discrepancy. Gene expression levels do not always correlate with protein expression and protein activity levels, which could be a reason for the observed increase of gene expression and decrease of the final product. Another explanation might be that residual blood was left in the tissue even after thorough washing. It is well known that lung tissue is well perfused and residual blood might remain. The decreased levels of galactosylated glycans found in the tissue samples could be a reflection of the decreased galactosylation previously reported on IgG (43) (44) (45) (46) . Furthermore, normal lung tissue is typically better perfused than tumor lung tissue, which might also contribute to the observation of decreased levels of the in blood typically high abundant biantennary galactosylated glycans.
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